BI 409306

Drug Profile

BI 409306

Alternative Names: BI409306; SUB 166499

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Neuropsychotherapeutics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Schizophrenia
  • Phase I Cognition disorders

Most Recent Events

  • 10 Aug 2017 Phase I development in healthy volunteers is ongoing in South Korea (NCT03193307)
  • 28 Jul 2017 Boehringer Ingelheim plans a phase II trial for Psychotic disorders (Prevention, In children, In adolescents, In adults) (NCT03230097)
  • 11 Jul 2017 Boehringer Ingelheim completes a drug-drug interaction phase I trial in Healthy volunteers in Germany (PO) (NCT03151499)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top